NCT01612000View on ClinicalTrials.gov

Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

341

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

August 31, 2013

Study Completion Date

December 31, 2013

Conditions
Influenza
Interventions
BIOLOGICAL

PanBlok

Intramuscular injection

BIOLOGICAL

rHA adjuvant

Intramuscular injection

Trial Locations (5)

14627

University of Rochester Center for Vaccine Studies, Rochester

68134

Meridian Clinical Research, Omaha

77030

Baylor College of Medicine, Houston

78705

Benchmark Reseach, Austin

84124

Jean Brown Research, Salt Lake City

All Listed Sponsors
lead

Protein Sciences Corporation

INDUSTRY

NCT01612000 - Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults | Biotech Hunter | Biotech Hunter